カテゴリ： GlobalData, アメリカ, 企業調査

Selecta Biosciences Inc (SELB)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Selecta Biosciences Inc (SELB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8047
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Selecta Biosciences Inc (Selecta Biosciences) is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company’s pipeline products include SEL-212, SEL-403, SEL-302 and SEL-302. It utilizes synthetic vaccine particle (SVP) technology platform to incorporate a wide range of antigens and immunomodulators, for the development of products that induce antigen-specific tolerance or activate the immune system. Selecta Biosciences develops products for the treatment of infections, central nervous system diseases, cancer, allergies, cardiovascular diseases, autoimmunity, metabolic diseases, asthma and acute and chronic inflammatory conditions. The company collaborates with pharma companies to develop drugs for allergy and autoimmune diseases. Selecta Biosciences is headquartered in Watertown, Massachusetts, the US.

Selecta Biosciences Inc (SELB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Selecta Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Selecta Biosciences Raises USD38 Million in Series E Financing 12
Selecta Bioscience Raises USD6 Million in Venture Financing 14
Selecta Biosciences Raises More than USD20 Million in Venture Financing 15
Selecta Biosciences Raises USD4.4 Million in Venture Financing 17
Selecta Biosciences Raises USD6 Million in Venture Financing 18
Selecta Biosciences Raises USD5.3 Million in Venture Financing 19
Private Equity 20
Reinet Investments Invests USD4.43 Million in Selecta Biosciences 20
Partnerships 21
Selecta Biosciences Enters into Research Agreement with Genethon 21
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 22
Licensing Agreements 23
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 23
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 25
Selecta Biosciences Enters into Licensing Agreement with Massachusetts Eye and Ear Infirmary 27
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 28
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 29
Equity Offering 30
Selecta Biosciences Files Registration Statement to Raise Funds through Public Offering of Shares 30
Selecta Biosciences Raises USD50 Million in Private Placement of Shares and Warrants 31
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 32
Selecta Biosciences Raises USD70 Million in IPO 34
Selecta Biosciences Inc – Key Competitors 36
Selecta Biosciences Inc – Key Employees 37
Selecta Biosciences Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 08, 2018: Selecta Biosciences announces second quarter 2018 financial results and provides corporate update 39
May 09, 2018: Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update 41
Mar 15, 2018: Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 42
Nov 07, 2017: Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update 44
Aug 11, 2017: Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update 46
May 11, 2017: Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update 48
Mar 27, 2017: Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 50
Corporate Communications 53
Sep 27, 2018: Selecta Biosciences names Carsten Brunn, Ph.D. as President and Chief Executive Officer 53
Jan 02, 2018: Massachusetts Selecta Biosciences’ CEO to Retire at the End of 2018 54
Jan 02, 2018: Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan 55
Oct 26, 2017: Selecta Biosciences Announces Important Additions to Senior Leadership Team 56
Product News 57
05/01/2017: Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy 57
Clinical Trials 58
Mar 12, 2018: Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma 58
Jan 09, 2018: Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-R 59
Jan 02, 2018: Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy 60
May 15, 2017: Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy 61
May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention 62
Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Celiac Disease Treatment 63
Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Selecta Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Selecta Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Selecta Biosciences Raises USD38 Million in Series E Financing 12
Selecta Bioscience Raises USD6 Million in Venture Financing 14
Selecta Biosciences Raises More than USD20 Million in Venture Financing 15
Selecta Biosciences Raises USD4.4 Million in Venture Financing 17
Selecta Biosciences Raises USD6 Million in Venture Financing 18
Selecta Biosciences Raises USD5.3 Million in Venture Financing 19
Reinet Investments Invests USD4.43 Million in Selecta Biosciences 20
Selecta Biosciences Enters into Research Agreement with Genethon 21
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 22
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 23
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 25
Selecta Biosciences Enters into Licensing Agreement with Massachusetts Eye and Ear Infirmary 27
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 28
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 29
Selecta Biosciences Files Registration Statement to Raise Funds through Public Offering of Shares 30
Selecta Biosciences Raises USD50 Million in Private Placement of Shares and Warrants 31
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 32
Selecta Biosciences Raises USD70 Million in IPO 34
Selecta Biosciences Inc, Key Competitors 36
Selecta Biosciences Inc, Key Employees 37
Selecta Biosciences Inc, Subsidiaries 38

List of Figures
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Selecta Biosciences Inc (SELB)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Public Joint-Stock Company Commercial Bank Privatbank
    Public Joint-Stock Company Commercial Bank Privatbank - Strategy, SWOT and Corporate Finance Report Summary Public Joint-Stock Company Commercial Bank Privatbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Therapure Biopharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Therapure Biopharma Inc (Therapure) is a biotherapeutics company that enhances patient care through its three divisions: therapure biomanufacturing, therapure innovations and evolve biologics. The company's therapure biomanufacturing division offers pipeline products such as TBI 301, TBI 302 …
  • Guess?, Inc.：戦略・SWOT・企業財務分析
    Guess?, Inc. - Strategy, SWOT and Corporate Finance Report Summary Guess?, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Ildong Pharmaceutical Co Ltd (000230)：企業の財務・戦略的SWOT分析
    Summary Ildong Pharmaceutical Co Ltd (IPC) is a manufacturer of pharmaceutical products. The company offers finished drugs, health foods and foods, raw material drugs, cosmetics and medical devices and others. Its raw material drugs comprise synthesis, probiotics, vitamins and biometabolites. IPC al …
  • Memphasys Ltd (MEM)-医療機器分野：企業M&A・提携分析
    Summary Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd is a bio-separations company that develops and commercializes separation techniques based on its membrane technology. The company develops felix, a non-DNA damaging lab instrument for sperm separation that separates sperm from semen samp …
  • CKE Restaurants Holdings Inc.：企業の戦略・SWOT・財務分析
    CKE Restaurants Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary CKE Restaurants Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • GS Yuasa Corp (6674)：企業の財務・戦略的SWOT分析
    GS Yuasa Corp (6674) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • MorphoSys AG (MOR)：企業の財務・戦略的SWOT分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid a …
  • Saudi Electricity Co：企業の発電所・SWOT分析2018
    Saudi Electricity Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • 10X Genomics, Inc.：製薬・医療：M&Aディール及び事業提携情報
    Summary 10X Genomics, Inc. (10X Genomics) is engaged in developing an innovative genomics platform. The company’s product pipeline comprises of chromium controller, single cell ATAC sequencer and single cell with barcode technology. It offers single cell gene expression, single cell immune profiling …
  • SolaCom Technologies, Inc.：企業の戦略・SWOT・財務情報
    SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • DTEK Energy BV：企業の戦略的SWOT分析
    DTEK Energy BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Pharming Group NV (PHARM)：製薬・医療：M&Aディール及び事業提携情報
    Summary Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops nutritional products for the treatment of genetic diseases and unmet medical needs. The company’s flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for …
  • Zimplats Holdings Ltd：企業の戦略・SWOT・財務情報
    Zimplats Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Zimplats Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Virgin Australia Holdings Limited：企業のM&A・事業提携・投資動向
    Virgin Australia Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Virgin Australia Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Coor Service Management Holding AB：企業の戦略・SWOT・財務情報
    Coor Service Management Holding AB - Strategy, SWOT and Corporate Finance Report Summary Coor Service Management Holding AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Koki Holdings Co Ltd：企業の戦略的SWOT分析
    Koki Holdings Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Fidelity Life Assurance of Zimbabwe Ltd：企業の戦略・SWOT・財務情報
    Fidelity Life Assurance of Zimbabwe Ltd - Strategy, SWOT and Corporate Finance Report Summary Fidelity Life Assurance of Zimbabwe Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Baron Oil Plc (BOIL)：企業の財務・戦略的SWOT分析
    Summary Baron Oil Plc (Baron Oil), formerly Gold Oil PLC is an oil and gas exploration and production company. The company identifies and develops crude oil and natural gas interests in Latin America including Peru and Colombia. It also holds working interests of Nancy Burdine Maxine oil field, oil …
  • Covis Pharma Sarl-製薬・医療分野：企業M&A・提携分析
    Summary Covis Pharma Sarl (Covis Pharma), a subsidiary of Concordia International Corp is a specialty pharmaceutical company that develops and markets drugs for the treatment of life-threatening conditions and chronic illnesses. The company develops products for central nervous system and rheumatic …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆